Abstract 333P
Background
FDG-PET/CT and Thallium SPECT (TL) which are radioisotope examination are inspection used as diagnostic imaging in the malignant tumors conventionally, and it is reported when useful for a stage diagnosis of the lung cancer. It was common to use the CT imaging according to the RECIST criteria for the effect judgment of cytotoxic agents and molecular target agents. In determining the efficacy of immune checkpoint inhibitors (ICIs), we often experienced that the assessment on CT imaging and the true effect do not match. Therefore, we planned a prospective study to evaluate whether FDG-PET/CT and TL examination is useful for ICI effect judgment. We examined the correlation between SUV differences on PET examination before treatment and 2 months after treatment initiation and RECIST evaluation.
Methods
A total of 18 advanced NSCLC patients treated at Kansai Medical University Hospital from September 2017 to September 2018 using ICI monotherapy were enrolled in this study. We examined the correlation with a PERCIST response rate and the response rate that went to the CT evaluation using RECIST1.1.
Results
The median age was 74 years. There were 15 men and three women. 15 cases were evaluable both before and two months after treatment initiatoin. There were CR/PR/SD/PD;0/3/7/5 by RECIST evaluation, and the curative effect judgment by FDG-PET were CMR/PMR/SMD/PMD; 1/3/6/5. 1 case was PD in RECIST, but was PMR in FDG-PET.The PR case tended to be higher in Tl accumulation after the treatment than an SD and PD cases.
Conclusions
The effect measurement by FDG-PET showed usefulness with more than that of RECIST evaluation and Tl-SPECT seems to have the potential to be useful in determining the effect of ICIs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Takayasu Kurata.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract